started · updated
CBL-514 injection shows promise in destroying visceral fat cells
Clinical trials for a new injectable drug, CBL-514, have shown promising results in treating obesity by targeting fat cells through apoptosis, or programmed cell death. Unlike traditional weight loss methods that primarily shrink fat cells, this approach aims to destroy them, potentially preventing the weight regain often seen after GLP-1 treatments.
Two Phase 2 trials, CBL-0204 and CBL-0205, included 107 and 173 participants, respectively. Analysis of a 41-person subgroup revealed that those receiving injections for 12 weeks experienced an average 12.01 percent reduction in visceral fat. In contrast, the placebo group saw an average increase of 5.68 percent in visceral fat over the same period.
Endocrinologist Timothy Garvey of the University of Alabama at Birmingham noted that while the cosmetic benefits of subcutaneous fat loss are significant, the primary health advantages lie in the reduction of visceral fat and subsequent improvements in blood pressure and cholesterol levels. These findings were presented at international conferences but have not yet undergone peer review.
Entities
CBL-514 · Timothy Garvey · University of Alabama at Birmingham
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] The placebo group experienced an average visceral fat increase of 5.68 percent during the same period. www.fehmarn24.de · www.hna.de · www.sciencealert.com
- [○ 1 SOURCE] CBL-514 has shown effectiveness in reducing both subcutaneous and visceral fat. www.sciencealert.com
- [● 3 SOURCES] Phase 2 clinical trials CBL-0204 and CBL-0205 involved 107 and 173 participants respectively. www.fehmarn24.de · www.hna.de · www.sciencealert.com
- [● 3 SOURCES] The injectable drug CBL-514 reduces visceral fat by inducing apoptosis, or programmed cell death, in fat cells. www.fehmarn24.de · www.hna.de · www.sciencealert.com
- [● 3 SOURCES] In a subset of 41 participants, CBL-514 injections over 12 weeks resulted in an average visceral fat reduction of 12.01 percent. www.fehmarn24.de · www.hna.de · www.sciencealert.com
- [● 3 SOURCES] Timothy Garvey expects the drug to improve metabolic risk factors such as blood pressure and cholesterol levels. www.fehmarn24.de · www.hna.de · www.sciencealert.com